These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7898254)

  • 21. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center.
    Ducruet T; Levasseur MC; Des Roches A; Kafal A; Dicaire R; Haddad E
    J Allergy Clin Immunol; 2013 Feb; 131(2):585-7.e1-3. PubMed ID: 23040368
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.
    Bal K; Kałuzińska-Parzyszek I; Sobocińska A; Podlecka D; Jerzyńska J; Stelmach I
    Indian J Pediatr; 2015 Aug; 82(8):768-9. PubMed ID: 25786586
    [No Abstract]   [Full Text] [Related]  

  • 23. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
    Fu LW; Song C; Isaranuwatchai W; Betschel S
    Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
    Rubinstein A; Mabudian M; McNeil D; Patel NC; Wasserman RL; Gupta S; Carrasco P; Chen J; Garcia E; Nagy A; Yel L
    J Clin Immunol; 2024 Aug; 44(8):181. PubMed ID: 39158670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomics of immunoglobulins and indications for their use.
    Guillevin L
    Curr Opin Allergy Clin Immunol; 2013 Jul; 13 Suppl 2():S53-5. PubMed ID: 23873314
    [No Abstract]   [Full Text] [Related]  

  • 26. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home.
    Ochs HD; Lee ML; Fischer SH; Delson ES; Chang BS; Wedgwood RJ
    J Infect Dis; 1987 Oct; 156(4):652-4. PubMed ID: 3624908
    [No Abstract]   [Full Text] [Related]  

  • 27. 20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.
    Wasserman RL; Stein MR; Younger ME; Fatteh S; Haddad E
    Ann Allergy Asthma Immunol; 2016 Jul; 117(1):93-4. PubMed ID: 27236217
    [No Abstract]   [Full Text] [Related]  

  • 28. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.
    Albin S; Cunningham-Rundles C
    Immunotherapy; 2014; 6(10):1113-26. PubMed ID: 25428649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.
    Brasileiro A; Fonseca Oliveira J; Pinheiro S; Paiva-Lopes MJ
    Lupus; 2016 May; 25(6):663-5. PubMed ID: 26846694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.
    Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH;
    Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoglobulin treatment in primary antibody deficiency.
    Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
    Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
    Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
    J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 34. IVIG in autoimmune disease - Potential next generation biologics.
    Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
    Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of patients with primary antibody deficiencies in Germany].
    Borte M; Oertelt C; Högy B
    Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of intravenous immunoglobulin (IVIG) therapy in adults.
    Herrod HG
    Allergy Proc; 1994; 15(6):309-12. PubMed ID: 7721079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Polyvalent immunoglobins in general pediatrics: what place, what risk, and what cost?].
    Dommergues JP; Bader-Meunier B
    Arch Pediatr; 1999; 6 Suppl 2():397s-399s. PubMed ID: 10370548
    [No Abstract]   [Full Text] [Related]  

  • 40. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.
    Vultaggio A; Azzari C; Milito C; Finocchi A; Toppino C; Spadaro G; Trizzino A; Baldassarre M; Paganelli R; Moschese V; Soresina A; Matucci A
    Clin Drug Investig; 2015 Mar; 35(3):179-85. PubMed ID: 25672929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.